Multiple Sclerosis and Electroconvulsive Therapy

Woersching, Joanna
April 2009
International Student Journal of Nurse Anesthesia;Spring2009, Vol. 8 Issue 1, p4
Academic Journal
Case Study
The article presents a case study on a 47 year old Caucasian female, who has been presented for first electroconvulsive therapy session. It is noted that there are several anesthetic matter that are to be considered in dealing with multiple sclerosis (MS), which include the exacerbation of symptoms that have resulted from changes in temperature and ventilatory compromise. Meanwhile, it is suggested that though systematic effects of electroconvulsive therapy for the said disease cannot be predicted, patients having advanced MS disease have the possibility to exhibit rise of cardiovascular instability out of autonomic dysfunction.


Related Articles

  • Mitoxantrone slowed progression of disability and reduced relapses in multiple sclerosis. Hartung, H. P.; Gonsette, R.; König, N. // Evidence Based Medicine;Sep2003, p148 

    The article presents a study that investigates the outcome of mitoxantrone treatment in slowing the progression and relapses in patients with multiple sclerosis (MS). It describes the procedure of the study which observes 194 patients and their mitoxantrone treatment. It notes the result of the...

  • Autoantibody synthesis in primary progressive multiple sclerosis patients treated with interferon beta-1b. Bitsch, Andreas; Dressel, Alexander; Meier, Kathrin; Bogumil, Timon; Deisenhammer, Florian; Tumani, Hayrettin; Kitze, Bernd; Poser, Sigrid; Weber, Frank // Journal of Neurology;Dec2004, Vol. 251 Issue 12, p1498 

    We conducted an open-labeled clinical trial of interferon beta-1b (IFNB) treatment in 20 patients with primary progressive multiple sclerosis (PPMS) and longitudinally monitored autoantibodies against double-stranded DNA (dsDNA), thyroid peroxidase (TPO),myelin basic protein (MBP), myelin...

  • Stabilization of rapidly worsening multiple sclerosis for 36 months in patients treated with interferon beta plus cyclophosphamide followed by interferon beta. Patti, Francesco; Reggio, Ester; Palermo, Filippo; Fiorilla, Teresa; Politi, Guido; Nicoletti, Alessandra; Reggio, Arturo // Journal of Neurology;Dec2004, Vol. 251 Issue 12, p1502 

    Cyclophosphamide (CTX) is an alkylating agent related to nitrogen mustards whose anti-inflammatory and immunosuppressive effects have been utilised to treat selected cases of multiple sclerosis with a progressive and worsening course. To halt the progression of disease in patients refractory to...

  • Exploring motivations to seek and undergo prosthodontic care: an empirical approach using the Theory of Planned Behavior construct. Hélio Vieira, Antonio; Rodrigues Leles, Cláudio // Patient Preference & Adherence;2014, Vol. 8, p1215 

    Background: The debate within the multiple sclerosis (MS) community initiated by the chronic cerebrospinal venous insufficiency (CCSVI) hypothesis and the subsequent liberation procedure placed some people with MS at odds with health care professionals and researchers. Objective: This study...

  • Navigating the "liberation procedure": a qualitative study of motivating and hesitating factors among people with multiple sclerosis. Ploughman, Michelle; Harris, Chelsea; Hogan, Stephen H.; Murray, Cynthia; Murdoch, Michelle; Austin, Mark W.; Stefanelli, Mark // Patient Preference & Adherence;2014, Vol. 8, p1205 

    Background: The debate within the multiple sclerosis (MS) community initiated by the chronic cerebrospinal venous insufficiency (CCSVI) hypothesis and the subsequent liberation procedure placed some people with MS at odds with health care professionals and researchers. Objective: This study...

  • Oral treatment reduces multiple sclerosis flare-ups. Stein, Jill // Drug Topics;6/16/2008, Vol. 152 Issue 7, Special section p4 

    The article discusses the effect of oral treatment on patients with multiple sclerosis. According to a report, patients receiving investigational oral immunomodulator fingolimod remained relapse-free after three years of treatment. It describes the results of an extension study in 173 patients...

  • New treatments portend a hopeful course for MS. Galloway, Gloria; Kaplan, Deborah // Patient Care;May2005, Vol. 39 Issue 5, p56 

    Provides information on treatment options for multiple sclerosis (MS). Prevalence of MS in the middle part of North America, southern Australia and northern Europe; Phases in advanced disease; Characteristics of MS; Disease-modifying drugs for MS. INSET: Barthof criteria in the diagnosis of MS.

  • Disease-modifying therapies and symptomatic treatments for MS patients. Boothby, Lisa; Doering, Paul L. // Drug Topics;10/25/2004, Vol. 148 Issue 20, p37 

    This article aims to review the pharmacology, efficacy, and safety profiles for the common disease-modifying therapies used to control symptoms often encountered in multiple sclerosis patients. It presents an outline of what is known about the pathophysiology of multiple sclerosis (MS). It...

  • Factors associated with the risk of secondary progression in multiple sclerosis. Koch, M.; Uyttenboogaart, M.; van Harten, A.; De Keyser, J. // Multiple Sclerosis (13524585);Jul2008, Vol. 14 Issue 6, p799 

    Objective To investigate factors associated with the risk of secondary progression in relapsing-remitting onset multiple sclerosis (MS). Methods We used Kaplan-Meier survival analyses and a multivariable Cox regression model to estimate the influence of the factors: gender, age at disease onset,...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics